Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 18, 2025
Product Development
Remaking Roche
How the once-dominant cancer company has overhauled its strategy for long-term growth
BioCentury | Jul 23, 2024
Data Byte
Accelerated approvals of Epkinly, Augtyro, Krazati among FDA’s June label expansions
The month also brought conversions to full approval for Retevmo and Sirturo
BioCentury | Nov 16, 2023
Deals
Nov. 16 Quick Takes: Q32 takes merger route to NASDAQ via Homology deal
Plus: SpringWorks’ neurofibromatosis program headed for NDA and updates from Astellas, Propella, BMS, Merck, Nature’s Toolbox, Apollomics and Avistone
BioCentury | Oct 31, 2023
Finance
Oct. 30 Quick Takes: VCs pile in for MapLight’s $225M series C
Plus: Deciphera gets lift from TGCT readout and updates from Hengrui, Merck KGaA, AnHeart, Nippon Kayaku, Novartis, GSK and more
BioCentury | May 31, 2023
Deals
May 30 Quick Takes: China deals for C4, Adcendo
Plus: GreenLight accepts a take-private offer, while Atea rejects one; and updates from Amylyx, Lexicon, Pfizer, BMS, Iovance and more
BioCentury | Mar 11, 2023
Emerging Company Profile
Opna Bio: targeting FMRP to treat cancer
Company’s other five small molecules come from CEO Gideon Bollag’s former company, Plexxikon
BioCentury | Jun 3, 2022
Deals
With standard-of-care aim for precision therapy, BMS pays high premium for Turning Point
In $4.1B deal, pharma pays more than double the biotech’s market valuation to gain targeted lung cancer therapy repotrectinib
BioCentury | Jul 30, 2021
Translation in Brief
Stanford, Tempus unveil high-throughput screening platforms; plus Blueprint, Editas, Prothena, AlzeCure and more
BioCentury’s roundup of translational news
BioCentury | Jul 14, 2020
Deals
Roche deal clears path for Blueprint’s financial independence
Blueprint receives $775M up front, diagnostic capabilities via licensing deal for RET inhibitor pralsetinib
BioCentury | Jul 7, 2020
Deals
Adding to targeted oncology portfolio, Zai gains China rights to Turning Point’s repotrectinib
Items per page:
1 - 10 of 153